Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-1.90%
SPX
-2.71%
IXIC
-3.56%
FTSE
-0.86%
N225
-1.01%
AXJO
-0.13%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Overview

Loading chart...
Join our newsletter to keep up to date with us!

Key Stats

Market Cap
53.29M
Dividend Yield
0.00%
P/E Ratio
-1.26
EPS
-0.73
Revenue
-
Avg. Volume
5.31M

Recently from Cashu

publisher logo
Cashu

Skye Bioscience Makes Significant Progress in Cannabinoid Therapies for Ocular Conditions

1 day ago
publisher logo
Cashu

Skye Bioscience Faces Setbacks After Disappointing Nimacimab Study Results

2 days ago
publisher logo
Cashu

Skye Bioscience's Nimacimab Phase 2a Results Spark Concerns Over Drug's Future Viability

3 days ago

About

What does SKYE do?
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
Sector
💻 Health Care
IPO
CEO
Employees
16
Headquarters
California, USA
Website
https://skyebioscience.com
Stocks
Health Care
skye
Skye Bioscience
NASDAQ: SKYE
+0.02 (+0.87%)
1.735
USD
At close at Oct 10, 20:41 UTC
Summary
News
Signals
Benchmarks
Financials